Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Business Wire
12d
Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Secret Service admits failure
Actress Crosby dies at 90
Ga. suspect's mom indicted
Russia threatens retaliation
Feds subpoena Schaeffer
Pandas leaving for China
Drug price challenge revived
WI high court to decide
Rejects CNN debate invite
Released after guilty plea
SC 1st execution in 13 years
Boeing defense chief exits
House repeals emission rules
1st rabies outbreak in seals
Hiker injured in bear attack
144K+ Mavericks recalled
FDA approves flu vaccine
$230 million crypto theft
Sesame Place suit verdict
Sues pharmacy middlemen
CAH sues for trespassing
TN abortion law blocked
Biden hosts 'Quad' summit
Hand count approved in GA
Top Hezbollah leader killed?
J&J unit files for bankruptcy
CA bill to protect kids online
Bill to boost security OK'd
Beirut strike death toll
ISR strike on Gaza school
In-person voting begins
Feedback